F
F. Mandel
Researcher at Pfizer
Publications - 37
Citations - 1054
F. Mandel is an academic researcher from Pfizer. The author has contributed to research in topics: Ziprasidone & Pregabalin. The author has an hindex of 16, co-authored 37 publications receiving 951 citations. Previous affiliations of F. Mandel include North Shore University Hospital & University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
High-Dose Sertraline Strategy for Nonresponders to Acute Treatment for Obsessive-Compulsive Disorder: A Multicenter Double-Blind Trial
Philip T. Ninan,Lorrin M. Koran,Ari Kiev,Jonathan R. T. Davidson,Steven A. Rasmussen,John Zajecka,Delbert Robinson,Paul Crits-Christoph,F. Mandel,Carol Austin +9 more
TL;DR: Greater symptom improvement was seen in the high-dose sertraline group compared to the 200-mg/day dose group during continuation treatment, and Administration of higher than labeled doses of selective serotonin reuptake inhibitors may be a treatment option for certain OCD patients who fail to respond to standard acute treatment.
Journal ArticleDOI
Differences between adolescents and young adults at presentation to an eating disorders program
TL;DR: It is confirmed that there are important differences between adolescents and adults that must be taken into account in the evaluation and treatment of patients with eating disorders.
Journal ArticleDOI
Efficacy of pregabalin and venlafaxine-XR in generalized anxiety disorder: results of a double-blind, placebo-controlled 8-week trial
Siegfried Kasper,Barry K. Herman,Giancarlo Nivoli,Michael Van Ameringen,Antonino Petralia,F. Mandel,F. Baldinetti,Borwin Bandelow +7 more
TL;DR: PGB was a safe and effective treatment of GAD, with a significantly earlier onset of anxiolytic activity than VXR.
Journal ArticleDOI
Efficacy of pregabalin in depressive symptoms associated with generalized anxiety disorder: a pooled analysis of 6 studies.
TL;DR: Pregabalin, an alternative treatment option for GAD with a novel mechanism of action, also demonstrated efficacy in treating depressive symptoms typically encountered in GAD patients.
Journal ArticleDOI
Determinants of Antipsychotic Response in Schizophrenia: Implications for Practice and Future Clinical Trials
Jonathan Rabinowitz,Nomi Werbeloff,Ivo Caers,F. Mandel,Virginia L. Stauffer,François Menard,Bruce J. Kinon,Shitij Kapur +7 more
TL;DR: Proof-of-concept trials can be shorter and efficiency improved by including an even distribution of sexes and of patients with prominent symptomatology, thus reducing patient exposure to placebo and experimental treatments.